Prevalence of systemic lupus erythematosus amongst child-bearing female patients attending University of Port Harcourt Teaching Hospital, Port Harcourt, Rivers State, Nigeria

Asuzu-Samuel Henrrietta Ogadimma; Oluwatayo, Beatrice Olatundun

doi:10.30574/gscbps.2021.14.3.0052

Authors

Asuzu-Samuel Henrrietta Ogadimma Biomedical Technology Option, School of Science Laboratory Technology, University of Port Harcourt, Choba, Rivers State, Nigeria.
Oluwatayo, Beatrice Olatundun Department of Haematology & Blood Group Serology, Federal College of Veterinary & Medical Laboratory Technology, Vom, Plateau State, Nigeria.

DOI:

https://doi.org/10.30574/gscbps.2021.14.3.0052

Keywords:

Syetemic, Lupus erythematosus, Immune, Antibody, Inflammation

Abstract

Systemic lupus erythematosus (SLE), a chronic and progressive multisystem autoimmune disorder is chiefly mediated by immune complexes in which the body’s immune system produce antibody (mostly antinuclear antibody) against normal cells and organs leading to inflammatory injuries. Several studies on this disease have been done in different parts of the world but very little exist in Nigeria, particularly in Port Harcourt. The study aim to determine the prevalence of systemic lupus erythematosus in Child-bearing female patients between the age ranges of 15 – 45 years, attending University of Port Harcourt Teaching Hospital, Rivers State, Nigeria. Ethical approval was sought for and obtained from the Ethical committee of the University of Port Harcourt Teaching Hospital. A total sample size of 207 was used. 5ml of blood samples were collected with 5ml syringe and needle into non-heparinized bottle from the antecubital fossa of recruited study group between 8am and 11am each day and was taken to the laboratory for analysis. De-fibrination method was used with the aid of centrifuge and microscope for detection of LE cell. Using an SLE latex reagent, the serum was analyzed for the presence of antinuclear antibody after centrifuging for 10mins. The SLE test kit used contained positive and negative controls to which the results were compared. Results gotten were all negative for the test group. This indicates a zero (0) prevalence level of systemic lupus erythematosus amongst child-bearing female patients attending the University of Port Harcourt Teaching Hospital.

Metrics

Metrics Loading ...

References

Edworthy SM. Clinical Manifestations of Systemic Lupus Erythematosus. In: Ruddy S, Harris ED, Sledge CB, Kelley WN, eds. Kelley's Textbook of rheumatology. 6th ed. Philadelphia: Saunders: 2001; 1105–1119.

Ramnik, S. Textbook of Medical Laboratory Technology; Systemic Lupus Erythematosus. Jitendar P Vij,Jaypee Brothers Medical Publishers (P), New Delhi. 2006; 804-805.

Cheesbrough, C. .District Laboratory Practice in Tropical Countries, part 2 Press Syndicate of the University of Cambridge, United Kingdom. 2004; 295-322.

Wahren-Herlenius, M, Dörner, T..Immunopathogenic mechanisms of systemic autoimmune disease. Lancet. 2013; 382: 819–831.

Earl S, Allison E. Textbook of Pediatric Rheumatology, sixth edition. 2011; 315-343.

Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sánchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, van Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS. Deviation and Validation of the Systemic Lupus Erythematosus International Collaborating Clinics Classification Criteria for SLE Arthritis Rhem. 2012; 64: 2677-2686.

Mok CC, Wong RW. Pregnancy in systemic lupus erythematosus. Postgrad. Med. J. 2002; 77: 157–65.

Paul E, Frank J. Systemic Lupus Erythematosus: Methods and Protocols. Humana Press. 2014; 1134.

Ohl k, Tenbrock k. Regulatory T cells in Systemic Lupus Erythematosus. Eur J Immunol. 2015; 45: 344-55.

McGrath H, Martinez-Osuna P, Lee FA. Ultraviolet-A1 (340–400 nm)Irradiation Therapy in Systemic Lupus Erythematosus. Lupus. 1996; 5: 269–274.

Dammacco F, Alberighi O, Ferraccioli G, Racanelli V, Casatta L, Bartoli E. Cyclosporine-A plus steroids versus steroids alone inthe 12-month treatment of systemic lupus erythematosus. Int J ClinLab Res. 2000; 30: 67–73.

Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheum. 1999; 26: 1275–1279.

Alvarez-Nemegyei J, Cobarrubias-Cobos A, Escalante-Triay F, Sosa-Munoz J, Miranda JM, andJara LJ. Bromocriptine in systemic lupus erythematosus: a double blind, randomized, placebo-controlled study. Lupus. 1998; 7: 414–419.

Johnson AE, Gordon C, Hobbs FD, Bacon PA. Undiagnosed Systemic Lupus Erythematosus in the Community. Lancet. 1996; 347: 367–369.

Danchenko N, Satia JA, Anthony MS. Epidemiology of System Lupus Erythematosus: a comparison of worldwide disease burden. Lupus. 2006; 15: 308–318.

Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet London, England. 2014.

Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998; 41: 778–799.

Sherer Y, Shoenfeld Y. Idiotypic network dysregulation: a common etiopathogenesis of diverse autoimmune diseases.Appl Biochem Biotechn. 2000; 83: 155-62.

Symmons D. Frequency of lupus in people of African origin. Lupus. 1995; 4(3): 176-8.

Stein M, Davis P. Rheumatic disorders in Zimbabwe: a prospective analysis of patients attending a rheumatic diseases clinic. Ann Rheum Dis. 1990; 49(6): 400-2.

Adelowo O, Oguntona S. Pattern of Systemic Lupus Erythematosus among Nigerians. J Clin Rheum. 2009; 28(6): 699-703.

Oduola OO, Uchegbu FA, Arogundade OG, Avwioro IS, Bello, Akinjole OO. Prevalence and Pattern of Lupus Erythematosus Cell Positivity in Diseases in Ile-Ife, Nigeria. Afr J of Biomed Res. 2005; 8: 135.